NAFLD prevalence | | |
Fibrosis stage | Median (minimum–maximum) | |
F1 | 0.588 (0.367–0.814) | Crossan et al28 |
F2 | 0.319 (0.119–0.526) |
F3 | 0.186 (0.050–0.440) |
F4 | 0.128 (0.039–0.907) |
Sensitivity of transient elastography for diagnosis of NAFLD | |
Fibrosis stage | Summary sensitivity (95% CI) | |
F≥1 | 0.87 (0.81 to 0.92) | Crossan et al28 |
F≥2 | 0.79 (0.72 to 0.85) |
F≥3 | 0.82 (0.74 to 0.88) |
F≥4 | 0.96 (0.83 to 0.99) |
Specificity of transient elastography for diagnosis of NAFLD | |
Fibrosis stage | Summary specificity (95% CI) | |
F≥1 | 0.76 (0.57 to 0.88) | Crossan et al28 |
F≥2 | 0.76 (0.71 to 0.80) |
F≥3 | 0.84 (0.78 to 0.89) |
F≥4 | 0.89 (0.85 to 0.92) |
Sensitivity of multiparametric MRI for diagnosis of NAFLD |
Any fibrosis | 0.86 | Banerjee et al27 |
Specificity of multiparametric MRI for diagnosis of NAFLD |
Any fibrosis | 0.93 | Banerjee et al27 |
Failure rates | Base case (range) | |
Transient elastography | 18.4% (12–50%) | Castéra et al25 |
Multiparametric MRI | 5% (2.5–10%) | Manufacturer data |
Costs | | |
Transient elastography | £52.44 | Crossan et al28 |
Liver biopsy | £983.70 |